van Duijnhoven, Franzel J. B.Jenab, MazdaHveem, KristianSiersema, Peter D.Fedirko, VeronikaDuell, Eric J.Kampman, EllenHalfweeg, Anoukvan Kranen, Henk J.van den Ouweland, Jody M. W.Weiderpass, ElisabeteMurphy, NeilLanghammer, ArnulfNess-Jensen, EivindOlsen, AnjaTjønneland, AnneOvervad, KimCadeau, ClaireKvaskoff, MarinaBoutron-Ruault, Marie-ChristineKatzke, VerenaKühn, TilmanBoeing, HeinerTrichopoulou, AntoniaKotanidou, AnastasiaKritikou, MariaPalli, DomenicoAgnoli, ClaudiaTumino, RosarioPanico, SalvatoreMatullo, GiuseppePeeters, Petra H. M.Brustad, MagrittOlsen, Karina StandahlLasheras, CristinaObón Santacana, MireiaSánchez, María JoséDorronsoro, MirenChirlaque, María DoloresBarricarte, AurelioManjer, JonasAlmquist, MartinRenström, FridaYe, WeiminWareham, NickKhaw, Kay-TeeBradbury, Kathryn E.Freisling, HeinzAune, DagfinnNorat, TeresaRiboli, ElioBueno de Mesquita, H. Bas2021-03-182021-03-182017-11-22https://hdl.handle.net/2445/175301Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer (PC). However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and PC incidence in European populations. We conducted a pooled nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study's second survey (HUNT2) cohorts. In total, 738 primary incident PC cases (EPIC n = 626; HUNT2 n = 112; median follow-up = 6.9 years) were matched to 738 controls. Vitamin D [25(OH)D2 and 25(OH)D3 combined] concentrations were determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smoking habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). Compared with a reference category of >50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42-1.20); 0.94 (0.72-1.22); 1.12 (0.82-1.53) and 1.26 (0.79-2.01) for clinically pre-defined categories of ≤25; >25 to 50; >75 to 100; and >100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with PC risk (p for trend = 0.23). Although these findings among participants from the largest combination of European cohort studies to date show increasing effect estimates of PC risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant.13 p.application/pdfengcc by-nc-nd (c) van Duijnhoven et al., 2017http://creativecommons.org/licenses/by-nc-nd/3.0/es/Càncer de pàncreesVitamina DPancreas cancerVitamin Dinfo:eu-repo/semantics/article2021-03-17info:eu-repo/semantics/openAccess29114875